Dale N Gerding, Oliver A Cornely, Simon Grill, Hilke Kracker, Anne Claire Marrast, Carl Erik Nord, George H Talbot, Martha Buitrago, Iulian Gheorghe Diaconescu, Claudia Murta de Oliveira, Liliana Preotescu, John Pullman, Thomas J Louie, Mark H Wilcox
BACKGROUND: Cadazolid is a novel quinoxolidinone antibiotic developed for treating Clostridium difficile infection. We aimed to investigate the safety and efficacy of cadazolid compared with vancomycin in patients with C difficile infection. METHODS: IMPACT 1 and IMPACT 2 were identically designed, multicentre, double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. IMPACT 1 was done in Australia, Brazil, Canada, France, Germany, Italy, the Netherlands, Peru, Poland, Romania, Spain, and the USA, and IMPACT 2 was done in Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czech Republic, Greece, Hungary, Israel, Romania, Slovakia, South Korea, the UK, and the USA...
January 29, 2019: Lancet Infectious Diseases